Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates
VANCOUVER--(BUSINESS WIRE)--DCx Biotherapeutics Corporation ('DCx') today announced an agreement with Repare Therapeutics Inc. ('Repare') (NASDAQ: RPTX) to (i) in-license Repare's discovery platform including certain program intellectual property, (ii) retain talent, (iii) acquire lease rights to laboratory facilities in Montreal and (iv) acquire laboratory equipment (the 'Transaction'). Combining the founding team's deep expertise in biologics innovation and development with the newly acquired discovery and translational capabilities, DCx is uniquely positioned to develop a new class of Multi-Modal Antibody Drug Conjugates ('MM-ADCs') against genetically-defined cancers.
DCx Strategy:
DCx addresses the root drivers of cancer, genetic mutations that lead to tumor proliferation and survival, by deconvoluting key cellular interdependencies using the MuSic™ platform. Understanding this roadmap enables the mutation-specific drugging of multiple critical targets to synergistically destroy tumors and induce long-term immune memory to achieve durable therapeutic responses while limiting side effects. Unlike current ADCs that deliver broadly chemotoxic payloads to a limited set of antibody targets, DCx's starting strategy is to develop MM-ADCs that optimize the synergy between, and simultaneously target, genetically-defined intracellular and cell-surface targets. The goals for this approach are to (i) increase efficacy, (ii) prolong activity by eliminating escape mechanisms and engaging the immune system, and (iii) improve tolerability while reducing side effects.
'DCx's founding vision is to realize the full potential of antibody drug conjugates by improving on the selectivity, potency, and tolerability for this promising class of therapeutics thus leading to improved clinical outcomes such as progression-free survival and overall survival,' said Ali Tehrani, PhD, Chief Executive Officer of DCx. 'This transaction with Repare is highly synergistic with our expertise and ambitions and accelerates the development of multiple development candidates over the next three years. We are also looking forward to embarking on this journey together with Repare's world-class preclinical research team that is joining the DCx family.'
Transaction:
DCx acquires rights to Repare's proprietary CRISPR, bioinformatics, and machine learning enabled platforms (now known collectively as the MuSic™ Platform) for the identification of surfaceome targets specific to genetic lesions in tumors
DCx obtains non-exclusive license to SNIPRx® and STEP 2 in support of discovering synthetic lethal and other targets
DCx acquires undisclosed surfaceome targets ('Acquired Targets') and antibodies discovered by Repare
DCx acquires undisclosed small molecule programs from Repare
DCx welcomes ~20 scientific and support colleagues spanning expertise in medicinal chemistry, molecular biology, bioinformatics, analytics, and pharmacology
DCx acquires lease rights to certain of Repare's Montreal laboratory facility and certain laboratory equipment
'We are excited with the potential in what DCx can bring to develop next-gen antibody drug conjugates and how this Transaction, together with a world-class management and scientific team, can meaningful propel these efforts forward,' comments Jean-François Pariseau, DCx Board Chair and Partner at Amplitude Ventures.
Launched out of Amplitude by Partner Ali Tehrani, DCx is the sixth company launched by Amplitude via its innovation platform. As part of this Transaction, Dr. Tehrani will assume the role of CEO. Other co-founders include Drs. David Poon and Ismael Samudio, and Ms. Candice Madalena. Together, they will leverage their deep experience in drug development, including most recently at Abdera and Zymeworks, which recently had the world's first bi-paratopic antibody therapeutic, Ziihera® (zanidatamab), approved by the FDA.
The Transaction is effective as of May 1, 2025. In consideration for the Transaction, Repare is eligible to receive, from DCX, the following:
Upfront and near-term cash payments, together with equity in DCx and a nominee to DCx's board of directors
Out-licensing, clinical, and commercial milestones, as well as low single-digit tiered sales royalties for products developed with Acquired Programs
Out-licensing, clinical, and commercial milestones for products developed with Acquired Targets
Other financial information is not disclosed.
About DCx Biotherapeutics Corp.
DCx Biotherapeutics is a preclinical-stage discovery and translational company addressing key dependencies of cancer lesions by developing multi-modal synergistic-targeting therapeutics with improved efficacy and tolerability while minimizing resistance. DCx's MuSic™ platform is enabled through the integration of CRISPR-based high-throughput functional screening combined with deep bioinformatics in support of advancing a pipeline of immune-stimulatory precision antibody drug conjugates to improve therapeutic outcomes against genetically-defined cancers. Visit www.dcxbio.com to learn more.
About Amplitude Ventures
Amplitude Ventures is a full-stack venture capital firm using a unique growth model to build companies with world-class management teams and to scale companies to breakout potential. With more than $500 million in assets under management and offices in Montreal, Toronto, Vancouver, and Calgary, Amplitude applies a proven, evidence-based approach to investing in leading precision medicine companies. Visit amplitudevc.com to learn more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Kessler Topaz Meltzer & Check, LLP Reminds MicroStrategy Incorporated d/b/a Strategy Investors of Important Deadline in Securities Fraud Class Action Lawsuit
RADNOR, PA - June 8, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that a securities class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy ('Strategy') ( NASDAQ: MSTR ) on behalf of those who purchased or otherwise acquired Strategy securities between April 30, 2024, and April 4, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is July 15, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Strategy losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Strategy's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the anticipated profitability of Strategy's bitcoin-focused investment strategy and treasury operations was overstated; (2) the various risks associated with bitcoin's volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. THE LEAD PLAINTIFF PROCESS: Strategy investors may, no later than July 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Strategy investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Yahoo
2 hours ago
- Yahoo
2 High-Growth Stocks to Buy and Hold for Great Long-Term Potential
CoreWeave is a promising stock to use to profit from the growing investment in AI infrastructure services. Axon stock recently hit new highs as it continues to report growing demand for its public safety solutions. 10 stocks we like better than CoreWeave › Investing in fast-growing companies that still have a large opportunity ahead for their products can help you build wealth. Artificial intelligence (AI) and public safety are promising industries to look for investments in 2025. Here are two stocks to ride these megatrends. AI is expected to add trillions in value to the economy over the long term, but this first requires substantial investment in data centers specially designed to handle AI computing workloads. CoreWeave (NASDAQ: CRWV) is a leader in offering AI infrastructure through the cloud for training models and other advanced workloads at scale. CoreWeave's revenue has exploded over the last year, growing from $189 million in Q1 2024 to $982 million in Q1 2025. Management expects 2025 revenue to be between $4.9 billion to $5.1 billion. For a long-term investor, CoreWeave is a unique stock with which to ride the growth of AI. It earns revenue through multiyear contracts or on-demand services, but most of its revenue is through committed contracts. This business model instills steady revenue and growing cash flows over time. The business is in the process of investing in technology to meet growing demand for its services. It reported a loss of $314 million last quarter. This mostly reflects the high upfront investment it's making in infrastructure, such as Nvidia's graphics processing units (GPUs), to offer its AI cloud platform to customers. However, CoreWeave is already showing the potential to be a very profitable business down the road. In Q1, its adjusted operating income increased 17% year over year to $163 million. But until it achieves higher margins, investors should expect the stock to be volatile. This is a world-class AI infrastructure provider that is trading at a price-to-sales multiple of 13 based on management's 2025 guidance. This is based on the company's current market cap (share price times shares outstanding) of $64 billion. Investors buying around this valuation can still expect to earn excellent returns over the next several years. Axon Enterprise (NASDAQ: AXON) (formerly Taser International) started over 30 years ago selling its Taser energy devices for law enforcement and self-defense. In recent years, the company has transformed into a services company with software solutions. This has grown its addressable market to an estimated $129 billion. Axon offers cloud-based evidence gathering software and body cameras, which has transformed the business from a device seller to a comprehensive solutions provider for public safety. Revenue from software and services grew 39% year over year to $263 million last quarter. Taser devices remain a key growth driver for the company. Since launching a few years ago, Taser 10 orders are growing twice as fast as the adoption of Taser 7. This indicates an expanding market for its products, which is a great sign for investors buying shares today. Axon's total revenue grew 31% year over year last quarter to $604 million. Axon is also benefiting from strong demand for Draft One, a service that uses AI to automatically fill out data entries and police reports. It saves hours of time from manual work, which has made it the fastest-growing software offering in Axon's history. Taser is potentially vulnerable to risks that investors should be aware of. It generates some revenue from government contracts, making it susceptible to spending cuts and higher compliance costs that could pressure its profit margin. It could also face public backlash and resistance from privacy concerns over its body camera products. But Axon's history shows that the need for enhanced public safety tools continues to grow. The stock surged to new highs following its first-quarter earnings report, which can be taken as a bullish signal on the company's future. Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Ballard has positions in CoreWeave and Nvidia. The Motley Fool has positions in and recommends Axon Enterprise and Nvidia. The Motley Fool has a disclosure policy. 2 High-Growth Stocks to Buy and Hold for Great Long-Term Potential was originally published by The Motley Fool
Business Upturn
2 hours ago
- Business Upturn
Where the Sea Meets the Skin: Shapellx Unveils Innovative New OceanHug™ Collection Made from Oyster Shells
By GlobeNewswire Published on June 8, 2025, 18:00 IST ORLANDO, Fla., June 08, 2025 (GLOBE NEWSWIRE) — Shapellx , a leading women's shapewear brand, proudly announces the launch of OceanHug™ – a seamless women's wear collection of intimates, outerwear, and shapewear pieces crafted with a first-of-its-kind fabric made from recycled oyster shells. The new sustainable, ocean-inspired collection enhances body contours while delivering the perfect balance of style, comfort, and sustainability. Every year, millions of pounds of oyster shells are discarded, eventually ending up in landfills. Shapellx believes that beauty should never come at the expense of the environment. Every OceanHug™ piece gives new purpose to 33 recycled oyster shells, integrating them into ethically produced, performance-driven fabrics. By turning marine waste into innovation, the collection represents a fresh take on circular fashion by finding a second life for shells that promotes innovation while reducing use of virgin materials. 'As sustainability becomes a top priority for both brands and consumers, Shapellx is proud to lead with innovative materials like oyster protein that combine environmental responsibility with performance-enhancing benefits,' said Shane Shi, Vice President of Shapellx. 'We're committed to delivering more sustainable alternatives without compromising on quality or comfort. OceanHug™ is just the beginning.' The lightweight yet form-fitting OceanHug™ yarn is engineered with breathable, moisture-wicking properties, feeling silky, cool, and comfortable to the touch. The fabric uniquely incorporates collagen peptides and oyster protein fiber, rich in amino acids and trace elements, which can help to nourish the skin and strengthen its barrier. OceanHug™ also offers antibacterial properties, reducing harmful bacteria growth by 2.56%, and is specially processed to be free from irritating chemicals, making it an excellent choice for those with sensitive skin. The new lineup, built with shapewear materials to hug and comfortably embrace the body, comes in soft hues of baby blue, lavender pink, oyster white, and more. The collection includes the following products: OceanHug™ Oyster Reborn Smoothing Bodysuit The delicate lace cup edges expand the coverage around the bust, enhancing the natural bust shape and curve. The waist and abdomen shaping works to tighten and smooth targeted areas for a comfortable, sculpted silhouette. Retails for $54 and is available in sizes S-XXL and colors black, brown, baby blue, oyster white, lavender pink and bright red. OceanHug™ Oyster Reborn T-Shirt Bra The OceanHug ™ Seamless Bra is made with high-elasticity yarn and butter-soft fabric for an ultimate comfort experience. The fixed one-piece cup design reduces the risk of cup-shifting for a supportive fit. The back closure is 7cm wide, compared to the traditional 3.5cm, providing better wraparound coverage and enhanced smoothing. Retails for $49 and is available in sizes S-3XL and colors black, brown, baby blue, oyster white, beige and lavender pink. OceanHug™ Oyster Reborn Smoothing Brief The briefs feature a mid-waist, hip-hugging seamless design for stable coverage, preventing unwanted digging and squeezing while delivering stretch to fit perfectly on all body types. Made from skin-friendly, soft modal fabric, it provides a gentle and refreshing touch on the skin. Retails for $9 and is available in sizes S-3XL and colors black, brown, baby blue, oyster white, beige and lavender pink. OceanHug™ Oyster Reborn Smoothing Cami The V-neckline highlights the collarbone, creating a feminine, flattering look. The built-in 3D molded cups comfortably lift and shape the bust for all-day support. It features an anti-slip grip at the bottom hem to prevent rolling and ensure a smooth, stable fit. The compression fabric around the waist and abdomen smooths the area and provides comfortable shaping. Retails for $49 and is available in sizes S-XXL and colors black, brown, baby blue, oyster white, beige and lavender pink. To celebrate both the OceanHug™ launch and World Ocean Day on June 8, Shapellx hosted a pop-up event in NoHo, New York. Attendees were able to experience the OceanHug™ fabric firsthand and received a special gift. Designed to suit your everyday life and standout moments, Shapellx's new OceanHug™ collection is available to purchase at . To learn more about the collection and keep up with the brand, follow along on Instagram and TikTok . About Shapellx Shapellx is a full-category shapewear brand built on cutting-edge shaping technology and refined design aesthetics. Through premium international retailers such as Nordstrom and its own online platform, Shapellx connects with women who value both quality and style. The brand is dedicated to meeting the dual needs of fashion expression and body contouring in everyday wear, empowering women to radiate confidence from the inside out. Contact:Melina Schaefer [email protected] A video accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
